Neurosense Therapeutics is trading at $0.43 (-7.57%) in after-hours trading, extending a weak stretch following its $0.47 regular-session close on July 31, 2026.
- The decline follows a July 30 filing for a $150 million securities shelf, which has sparked significant investor concerns regarding potential share dilution.
- Selling pressure was further intensified by an auditor’s going-concern warning included in the filing, highlighting the company's financial instability.
- The stock's sharp reaction is amplified by thin after-hours liquidity, which often leads to volatile moves on news related to financing risks.